BerandaGRF • BME
add
Grifols SA Class A
Tutup sebelumnya
€9,27
Rentang hari
€9,11 - €9,33
Rentang tahun
€7,32 - €13,70
Kapitalisasi pasar
5,95Â M EUR
Volume Rata-Rata
2,59Â jt
Rasio P/E
15,58
Hasil dividen
1,63%
Bursa utama
BME
Dalam berita
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (EUR) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 1,98Â M | 0,32% |
Biaya operasional | 353,11Â jt | 0,09% |
Penghasilan bersih | 98,25Â jt | 42,29% |
Margin laba bersih | 4,96 | 41,71% |
Penghasilan per saham | — | — |
EBITDA | 422,88Â jt | -14,62% |
Tarif pajak efektif | -13,21% | — |
Neraca
Total aset
Total liabilitas
| (EUR) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 849,00Â jt | -15,44% |
Total aset | 19,71Â M | -7,91% |
Total liabilitas | 12,11Â M | -5,39% |
Total ekuitas | 7,60 M | — |
Saham yang beredar | 680,58 jt | — |
Harga terhadap nilai buku | 1,20 | — |
Tingkat pengembalian aset | 4,39% | — |
Tingkat pengembalian modal | 5,04% | — |
Arus Kas
Perubahan kas bersih
| (EUR) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | 98,25Â jt | 42,29% |
Kas dari operasi | 430,86Â jt | -16,25% |
Kas dari investasi | -151,32Â jt | 15,45% |
Kas dari pembiayaan | -75,18Â jt | -173,90% |
Perubahan kas bersih | 203,82Â jt | -39,27% |
Arus kas bebas | 349,39Â jt | 243,02% |
Tentang
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
CEO
Didirikan
18 Nov 1940
Situs
Karyawan
25.258